id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0020,FDA,FDA-2012-D-0880,Final Guidance for Industry Generic Drug User Fee Amendments of 2012 - Questions and Answers Related t User Fee Assessments,Other,Guidance,2016-12-14T05:00:00Z,2016,12,2016-12-14T05:00:00Z,,2024-11-07T23:53:21Z,,1,0,0900006482409ef4
FDA-2012-D-0880-0018,FDA,FDA-2012-D-0880,Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments; Guidance for Industry; Availability,Notice,Notice of Availability,2016-11-18T05:00:00Z,2016,11,2016-11-18T05:00:00Z,,2016-11-18T17:35:39Z,2016-27761,0,0,09000064823a05f3
FDA-2012-D-0880-0019,FDA,FDA-2012-D-0880,Draft Guidance for Generic Drug User Fee Amendments of 2012 Questions and Answers,Other,Guidance,2016-11-18T05:00:00Z,2016,11,2016-11-18T05:00:00Z,,2024-11-12T06:16:24Z,,1,0,09000064823a0ef6